Answers are grounded in this paper and cite their sources.
Formulation optimization study demonstrates rapid dissolution and effective taste masking for ibuprofen extrudates, suggesting viable oral delivery for poorly soluble drugs.
This study presents a Quality by Design (QbD) strategy combined with Design of Experiments (DoE) to develop hybrid polymer-lipid hot-melt extruded (HME) formulations aimed at improving the dissolution rate and palatability of ibuprofen (IBU), a Biopharmaceutics Classification System (BCS) Class II drug with poor aqueous solubility. A fractional factorial design was applied to evaluate the influence of Eudragit EPO and Gelucire 48/16 (GLC) ratios on the preparation of IBU-loaded extrudates. Physicochemical characterisation of the micronised extrudates, using differential scanning calorimetry (DSC) and X-ray powder diffraction (XRPD), confirmed the formation of amorphous solid dispersions (98.0-99.8%). The DoE analysis demonstrated that the EPO/GLC ratio significantly affected crystallinity, particle size distribution, and dissolution performance. The optimised hybrid polymer-lipid formulations exhibited immediate drug release (> 80%) within 45 min. Furthermore, in vivo evaluation indicated effective taste masking and improved palatability.
No takes yet. Share an insight, caveat, or question.
Kolipaka et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: